Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GLOBAL BREAST IMPLANT PROPOSED LIABILITY SETTLEMENT

This article was originally published in The Gray Sheet

Executive Summary

GLOBAL BREAST IMPLANT PROPOSED LIABILITY SETTLEMENT allocates up to $81.5 mil. for foreign claimants who developed specified diseases and conditions following receipt of silicone gel implants. Under the proposed $4.25 bil. settlement ("The Gray Sheet" April 18, p. 8), $2.715 bil. would be allocated to a Disease Compensation Program that would furnish benefits for women who have one of the specified conditions or develop one in the next 30 years. Up to 3% of the funds in the disease compensation program will be available to foreign claimants.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel